NCT02161575 - Safety and Efficacy of Switching From Aflibercept to Ranibizumab in Patients With nAMD | Biotech Hunter

Enrollment

103

Participants

Timeline

Start Date

August 28, 2014

Primary Completion Date

September 14, 2017

Study Completion Date

September 14, 2017

Conditions

Neovascular Age-related Macular Degeneration

Interventions

DRUG

Ranibizumab

Intraveal injections of 0.5mg ranibizumab

Trial Locations (28)

45468

Novartis Investigative Site, Mühlheim

48149

Novartis Investigative Site, Münster

53127

Novartis Investigative Site, Bonn

76135

Novartis Investigative Site, Karlsruhe

80336

Novartis Investigative Site, München

04103

Novartis Investigative Site, Leipzig

DL3 6HX

Novartis Investigative Site, Darlington

CM20 1QX

Novartis Investigative Site, Harlow

CT1 3NG

Novartis Investigative Site, Canterbury

AB25 2ZN

Novartis Investigative Site, Aberdeen

IP4 5PD

Novartis Investigative Site, Ipswich

GU16 7UJ

Novartis Investigative Site, Frimley

BD9 6RJ

Novartis Investigative Site, Bradford

BT12 6BA

Novartis Investigative Site, Belfast

G75 8RG

Novartis Investigative Site, East Kilbride

G12 OYN

Novartis Investigative Site, Glasgow

NR31 6LA

Novartis Investigative Site, Great Yarmouth

HG2 7SX

Novartis Investigative Site, Harrogate

L7 8XP

Novartis Investigative Site, Liverpool

EC1V 2PD

Novartis Investigative Site, London

NW1 5QH

Novartis Investigative Site, London

SE5 9RS

Novartis Investigative Site, London

M13 9WL

Novartis Investigative Site, Manchester

OX3 9DU

Novartis Investigative Site, Oxford

SO16 6YD

Novartis Investigative Site, Southampton

SR2 9HP

Novartis Investigative Site, Sunderland

UB8 3NN

Novartis Investigative Site, Uxbridge

YO31 8HE

Novartis Investigative Site, York